Unfortunately, although many patients have achieved long-term survival benefits with PD-1/PD-L1 inhibitors, some patients have experienced rapid tumor progression after immunotherapy, known as hyperprogressive disease (HPD) (97, 98). The gene discussed is PDCD1; the disease is neoplasm.